Proteome-wide Anti-HCV and Anti-HIV Antibody Profiling for Predicting and Monitoring Response to HCV Treatment in HIV Co-infected Patients

摘要

We quantified antibody responses to the HCV proteome that are associated with sustained virologic response (SVR) in HIV/HCV co-infected patients treated with pegylated interferon and ribavirin. Analysis of pre- and post-treatment samples revealed significant decreases in the combined anti-core, anti-E1 and anti-NS4 HCV antibody titers in those with SVR, but not in the relapsers or non-responders. Furthermore, anti-p24 HIV antibody titers inversely correlated with treatment response. These results suggest that profiling anti-HCV antibody is useful for monitoring HCV therapy especially in discriminating between relapsers and SVRs at 48 weeks.